Astrazeneca (AZN) said Friday that results from a phase 3 trial of Imfinzi in combination with standard-of-care chemotherapy to treat certain gastric cancers met the primary endpoint of event-free survival.
Patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers were treated with neoadjuvant Imfinzi in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel before surgery, followed by adjuvant Imfinzi in combination with chemotherapy, then Imfinzi monotherapy.
Astrazeneca also said that for the secondary endpoint of overall survival, a "strong trend" was seen in the interim analysis that favors the Imfinzi-based regimen.
The adjunctive therapy more than doubled pathologic complete response rate in previously reported analysis of this trial in 2023, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。